# Cavadis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cavadis

- Industry: Biotechnology
- Headquarters: Utrecht, Netherlands
- Website: www.cavadis.com
- Latest round: Series A (May 26, 2009)
- Investors on record: 3

## About

Based in Utrecht, Netherlands, and founded in 2007, Cavadis B.V. is a biomedical company active in the field of atherosclerosis and the identification of patients with high cardiovascular risks. Heico Breek, formerly VP at Aventis Pharma now chairs the company as CEO. The company identified novel biomarkers useful in predicting cardiovascular events such as heart attacks and strokes. The company has developed biomarkers in plasma and atherosclerotic vessel wall tissue. In May 2009, Cavadis B.V raised Series A financing led by Thuja Capital along with returning investors ErasmusMC Biomedical Fund and Utrecht Holding B.V. 

Insufficiency of the traditional risk factors to accurately predict cardiovascular events led the company to develop immunoassays based on novel biomarkers. Such biomarkers distinguish patients as high-risk or low-risk and accordingly enable the company to develop stratification tools to provide personalized treatment and treat-to-target medication schemes. The company’s products include Cavadis Pipeline used for developing prognostic tests for identifying myocardial infarction (MI) and peripheral arterial diseases (PAD). A panel of biomarkers was being validated in the primary and secondary prevention cohorts to develop CAVARISK assays. The company subsequently developed CAVARISK CAD which a blood-based prognostic assay to identify patients at risk for coronary artery disease (CAD). The company has also identified a panel of differentially expressed exosomal biomarkers that are used in drug development for patient stratification and as surrogate endpoints in clinical trials.

In the future, the company aims to expand research into the development of novel biomarkers for predicting and preventing secondary cardiovascular events.

## Funding rounds

- Series A, May 26, 2009 — Thuja Capital, Erasmus MC Biomedical Fund, Utrecht Holding BV

## Investors

- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Series A
- Erasmus MC Biomedical Fund (https://capitalatlas.ai/funds/erasmus-mc-biomedical-fund) — Series A
- Utrecht Holding BV — Series A